3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Lymphoma, Large B-Cell, Diffuse
22
Breast Neoplasms
19
Lymphoma
14
Sarcoma
13
Lymphoma, Non-Hodgkin
9
Lymphoma, Follicular
8
Lymphoma, B-Cell
8
Hodgkin Disease
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Mantle-Cell
5
Immunoblastic Lymphadenopathy
5
Ovarian Neoplasms
4
Neoplasms
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Hepatocellular
4
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Primary Effusion
3
Chondrosarcoma
3
Triple Negative Breast Neoplasms
2
Solitary Fibrous Tumors
2
Sarcoma, Clear Cell
2
Plasmablastic Lymphoma
2
Osteosarcoma
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Liver Neoplasms
2
Interventions
Trastuzumab
4
pertuzumab
2
Docetaxel
2
palbociclib
1
Protons
1
Paclitaxel
1
Letrozole
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Enfuvirtide
1
Doxorubicin
1
Cyclophosphamide
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
HER2-positive Breast Cancer
×
Doxorubicin
×
Clear all
NCT02379585
2018-04-24
STEFNE
Western Regional Medical Center
Phase 1/2
Terminated
8 enrolled
1 chart